The Future of the U.S. Biologics and Biosimilars Treatment Market for Psoriasis
SKU ID :MP-11353702 | Published Date: 13-Oct-2017 | No. of pages: 104Contents Executive Summary 4 List of Figures 7 List of Tables 8 1. Psoriasis Market Overview 9 1.1. Disease background 9 1.2. Types of psoriasis 10 1.2.1. Plaque psoriasis 11 1.2.2. Guttate psoriasis 11 1.2.3. Inverse (flexural) psoriasis 11 1.2.4. Pustular psoriasis 11 1.2.5. Erythrodermic psoriasis 12 1.3. Pathophysiology 12 1.4. Etiology 12 1.4.1. Environmental factors 12 1.4.2. Genetic factors 12 1.4.3. Immunologic factors 14 1.5. Risk factors and co-morbidities 16 1.6. Epidemiology 16 1.7. Treatment options 17 1.7.1. Phototherapy 18 1.7.2. Topical treatments 18 1.7.3. Conventional systemic agents 18 1.7.4. Other systemic drugs 18 1.7.5. Biologics 18 1.8. Treatment Guidelines 19 1.8.1. Mild to moderate Psoriasis 22 1.8.2. Moderate Psoriasis 22 1.8.3. Moderate –to–severe psoriasis 22 1.8.4. Severe psoriasis 22 2. Psoriasis Treatment Market for Biologics 23 2.1. Introduction and Market Overview 23 2.2. Revenue Analysis for Biologics in the U.S. 30 2.3. Key marketed products for psoriasis treatment 33 2.3.1. Remicade (infliximab; Janssen) 38 2.3.2. Humira (adalimumab; AbbVie) 42 2.3.3. Stelara (ustekinumab; Janssen) 46 2.3.4. Cosentyx (secukinumab; Novartis) 50 2.3.5. Taltz (ixekizumab; Lilly) 55 2.3.6. Siliq (brodalumab; Valeant) 59 2.3.7. Tremfya (guselkumab; Janssen) 62 2.4. Key pipeline products for psoriasis treatment 65 2.4.1. Tildrakizumab; Merck / Sun Pharma 66 2.4.2. Cimzia (certolizumab pegol; UCB/Dermira Pharmaceuticals) 68 2.4.3. Risankizumab; AbbVie/Boehringer Ingelheim 70 2.5. Growth Drivers and Resistors for Biologics 71 2.5.1. Growth Drivers: 71 2.5.2. Resistors 73 2.6. Competitive Landscape ‒ Approved Products 75 2.7. Competitive Landscape ‒ Pipeline Products 77 3. Psoriasis Market for Biosimilars 79 3.1. Introduction and Market Overview 79 3.2. Approved biosimilars 79 3.2.1. Approved biosimilars in the U.S. 79 3.2.2. Revenue Analysis for Biosimilars in U.S. 81 3.2.3. Approved biosimilars in the EU 81 3.3. Pipeline Analysis 83 3.3.1. Clinical development ‒ Humira (adalimumab) biosimilars 84 3.3.2. Clinical development ‒ Enbrel (etanercept) biosimilars 84 3.3.3. Clinical development ‒ Remicade (infliximab) biosimilars 85 3.4. Biosimilars deals and partnerships 86 3.5. Growth Drivers and Resistors for Biosimilars 87 3.5.1. Growth Drivers 87 3.5.2. Resistors 90 3.6. Competitive Landscape ‒ Approved Biosimilars in the U.S. and EU 94 3.7. Competitive Landscape – TNF α Inhibitors Biosimilars Pipeline 96 References: 98 |
Table 1: Common sub-types of psoriasis Table 8: Plaque psoriasis clinical studies – Enbrel |
Figure 1: Common areas of distribution of psoriasis Figure 2: Psoriasis coverage and distribution Figure 3: Proposed schema of the evolution of a psoriatic lesion Figure 4: Comorbidities associated with psoriasis Figure 5: Burden of psoriasis by countries Figure 6: Psoriasis management algorithm Figure 7: Therapeutic targets for biologics in psoriasis Figure 8: Biological effects of TNF- α Figure 9: Schematic configuration of dominant TNF- α inhibitors Figure 10: The structure and function of the cytokines IL-12 and IL-23 Figure 11: IL-17-induced signaling pathways Figure 12: IL- 17 and IL 23 in the pathogenesis of psoriasis Figure 13: Sales estimates for biologics in psoriasis in U.S., 2016-21 Figure 14: Sales estimates forTNF-α inhibitor biologics in psoriasis in U.S., 2016-21 Figure 15: Sales estimates forIL-inhibitor biologics in psoriasis in U.S., 2016-21 Figure 16: SWOT analysis ‒ Enbrel Figure 17: Overall sales analysis ‒ Enbrel Figure 18: SWOT analysis ‒ Remicade Figure 19: Overall sales analysis ‒ Remicade Figure 20: SWOT analysis ‒ Humira Figure 21: Overall sales analysis ‒ Humira Figure 22: SWOT analysis ‒ Stelara Figure 23: Overall sales analysis ‒ Stelara Figure 24: SWOT analysis ‒ Cosentyx Figure 25: Overall sales analysis ‒ Cosentyx Figure 26: SWOT analysis ‒ Taltz Figure 27: Overall sales analysis ‒ Taltz Figure 28: SWOT analysis ‒ Siliq Figure 29: SWOT analysis ‒ Tremfya Figure 30: Sales estimates for biosimilars in psoriasis in U.S., 2016-21 |
- PRICE
-
$4000$8000Buy Now